About NUBEQA® (darolutamide) | Prostate Cancer (mCSPC, nmCRPC) Treatment

JUMP TO SECTION

NUBEQA is a pill

NUBEQA is a prescription medicine that’s approved to treat certain types of advanced prostate cancer.

NUBEQA may be the right option for your type of advanced prostate cancer

Your doctor can explain how NUBEQA works with your type of prostate cancer and what you can expect during treatment.

**NUBEQA is always taken with androgen deprivation therapy (ADT)* to treat prostate cancer**

METASTATIC

Prostate cancer that has spread to other parts of the body and responds to ADT

Graphic of NUBEQA (darolutamide) in combination with ADT alone or ADT+chemotherapy for patients with metastatic prostate cancer that responds to ADT

See the clinical studies

NON-METASTATIC

Prostate cancer that has not spread to other parts of the body and no longer responds to ADT

Graphic of NUBEQA (darolutamide) in combination with ADT for patients with non-metastatic prostate cancer that does not responds to ADT

See the clinical study

It is not known if NUBEQA is safe and effective in females and children.

*ADT refers to a medical or surgical treatment that lowers testosterone.

^†Chemotherapy=docetaxel.

How does NUBEQA delay prostate cancer growth?

Prostate cancer cells contain special proteins called androgen receptors. When the hormone testosterone attaches to these receptors, it can trigger processes that cause prostate cancer cells to grow.

NUBEQA is an androgen receptor blocker, which means it attaches to the androgen receptors inside cancer cells and blocks testosterone from attaching. By being designed to stop testosterone attaching, NUBEQA may help delay cancer cells from growing.

Illustration of how NUBEQA blocks androgen receptors in prostate cancer

How does NUBEQA delay prostate cancer growth?

Get an expert's perspective on NUBEQA

Tony Romo, former professional quarterback, sits down with Dr. Pedro Barata, an oncologist,
for a quick rundown on treatment with NUBEQA.

Tony Romo does not have prostate cancer and is not a NUBEQA patient.

See more conversations with Tony

Tony Romo, former professional quarterback, is celebrating the moments that matter to real NUBEQA patients.

Watch videos

Important Safety Information

Important Safety Information

Before taking NUBEQA, tell your healthcare provider about all your medical conditions, including if you:

have heart problems, high blood pressure, diabetes, or high amounts of fat or cholesterol in your blood (dyslipidemia)
have a history of seizures, brain injury, stroke, or brain tumors
have kidney or liver problems
are pregnant or plan to become pregnant. NUBEQA can cause harm to your unborn baby and loss of pregnancy (miscarriage)
have a partner who may become pregnant. Males who have female partners who may become pregnant should use effective birth control (contraception) during treatment and for 1 week after the last dose of NUBEQA. Talk with your healthcare provider about birth control methods
are breastfeeding or plan to breastfeed. It is not known if NUBEQA passes into breast milk

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. NUBEQA may affect the way other medicines work and other medicines may affect how NUBEQA works.

You should not start or stop any medicine before you talk with the healthcare provider that prescribed NUBEQA.

Know the medicines you take. Keep a list of them with you to show to your healthcare provider and pharmacist when you get a new medicine.

NUBEQA may cause serious side effects, including:

Heart disease. Blockage of the arteries in the heart (ischemic heart disease) that can lead to death has happened in some people during treatment with NUBEQA. Your healthcare provider will monitor you for signs and symptoms of heart problems during your treatment with NUBEQA. Call your healthcare provider or get medical help right away if you get chest pain or discomfort at rest or with activity, or shortness of breath during your treatment with NUBEQA.
Seizure. Treatment with NUBEQA may increase your risk of having a seizure. You should avoid activities where a sudden loss of consciousness could cause serious harm to yourself or others. Tell your healthcare provider right away if you have loss of consciousness or seizure during treatment with NUBEQA.

The most common side effects of NUBEQA include:

increase in liver function tests
decreased white blood cells (neutropenia)
feeling more tired than usual

The most common side effects of NUBEQA in combination with docetaxel include:

constipation
rash
decreased appetite
bleeding
weight gain
high blood pressure
decreased red blood cells (anemia)
high blood sugar levels
decreased white blood cells
increase in liver function tests
low blood calcium levels

NUBEQA may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of NUBEQA.

Call your healthcare provider for medical advice about side effects. You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

Please see the full Prescribing Information.

<span>WHAT IS NUBEQA<sup>®</sup>?</span>

WHAT IS NUBEQA^®?

NUBEQA^® (darolutamide) is a prescription medicine used to treat adults with prostate cancer:

that has not spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone
that has spread to other parts of the body and responds to a medical or surgical treatment that lowers testosterone
that has spread to other parts of the body and responds to a medical or surgical treatment that lowers testosterone in combination with docetaxel.

It is not known if NUBEQA is safe and effective in females or children.

© 2026 Bayer. All rights reserved. BAYER, the Bayer Cross and NUBEQA are registered trademarks of Bayer, and Access Services by Bayer is a trademark of Bayer.

Date of last update: 9/17/2026